
|Videos|May 19, 2020
Dr. Savvides on the Utility of Immunotherapy in Lung Cancer
Author(s)Panayiotis S. Savvides, MD
Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.
Advertisement
Panayiotis S. Savvides, MD, a medical oncologist at Mayo Clinic Arizona, discusses the utility of immunotherapy in lung cancer.
Documenting the efficacy of immunotherapy in lung cancer has revolutionized what patients have been offered over the past few years, says Savvides. The options that are avaliable to patients have significantly improved with these advances, adds Savvides. Interestingly, the safety profile of immunotherapies completely differs from that of cytotoxic chemotherapy regimens that the field had been using. Immunotherapy appears to have a more favorable safety profile, concludes Savvides.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































